Canada Recommends Funding Lecanemab for Early-Stage Alzheimer's Disease

The Canada Drug Agency recommended that lecanemab, proven to slow the progression of early-stage Alzheimer's disease, be covered under public drug…

Although Health Canada approved the drug in October, the agency had previously recommended against public funding in February due to concerns about efficacy and potential side effects such as brain swelling or…